LOAMS
ITCI

Lombard Odier Asset Management (Switzerland)’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Lombard Odier Asset Management (Switzerland)’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-61,882
Closed -$3.35M – 388
2023
Q1 		$3.35M Buy
61,882
+15,433
+33% +$746K 0.29% 83
2022
Q4 		$2.46M Buy
+46,449
New +$2.33M 0.2% 106

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lombard Odier Asset Management (Switzerland)'s ITCI Position: Q2 2023 in Review

Lombard Odier Asset Management (Switzerland) sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2023, closing a stake of 61,882 shares — an estimated $3.35M sold.

Lombard Odier Asset Management (Switzerland) first reported a position in ITCI in Q4 2022 and held it in 2 quarters. The position peaked at $3.35M in Q1 2023. 288 funds tracked by Wall St. Rank hold ITCI as of Q2 2023.

  • Lombard Odier Asset Management (Switzerland) reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2023 after selling out during the quarter.
  • Lombard Odier Asset Management (Switzerland) sold 61,882 Intra-Cellular Therapies Inc. shares in Q2 2023, an estimated $3.35M.
  • Lombard Odier Asset Management (Switzerland) first reported a position in Intra-Cellular Therapies Inc. in Q4 2022 and held it in 2 quarters.
  • Lombard Odier Asset Management (Switzerland)'s Intra-Cellular Therapies Inc. position peaked at $3.35M in Q1 2023.
  • 288 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2023.

Based on Lombard Odier Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 14 Aug 2023.